( h a dual serotoninand dopamine recepto...)Antipsychotic Iloperidone Results Show Favorable Akathisia Profile,Health

h a dual serotonin and dopamine receptor antagonist profile. Clinical trial experience with iloperidone suggests that this balanced antagonism may provide efficacy against positive and negative symptoms of schizophrenia, while causing reduced EPS and hyperprolactinemia relative to other available atypical antipsychotics. Iloperidone also appears to have a favorable weight and metabolic profile. In addition, Vanda is developing a genetic blood test to help identify those patients most likely to benefit from iloperidone.

Vanda has completed its Phase III program for iloperidone in schizophrenia and expects to file a new drug application (NDA) for the oral formulation in Q4 2007. Vanda is also developing a four-week injectable formulation of the compound.

About Schizophrenia

Schizophrenia is a chronic, severe and disabling brain disorder that affects approximately one percent of Americans. Patients suffering from schizophrenia exhibit a range of symptoms, which are classified into three broad categories:

    -- Positive symptoms reflect an excess or distortion of normal functions

       (e.g., hallucinations, delusions, thought and movement disorders).

    -- Negative symptoms represent a loss or decrease in the ability to

       initiate plans, speak, express emotion, or find pleasure in everyday

       life.

    -- Cognitive symptoms include problems with attention, memory or planning,

       and often interfere with normal routines.

Unmet Needs in Schizophrenia

Although there are many drugs approved to treat schizophrenia, including the commonly prescribed "atypical antipsychotics," a high degree of dissatisfaction remains among physicians and patients. The recent CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) study, conducted by the National Institute of Mental Health and reported in The New England Journal of Medicine, evaluated several antipsychotic medications and revealed that 74% of pa
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia
2. Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis